GlassScriptPhysician profile
Peter R Futrell
NPI 1912990391
$34,076.37
in general payments reported to CMS, 2019-2025
86 companies · $4,785 in 2025
The $4,785 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,453 · 2020: $5,056 · 2021: $6,874 · 2022: $4,364 · 2023: $3,963 · 2024: $4,581 · 2025: $4,785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $33.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,294.90 |
| Education | $33.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,389.48 | 2019-2025 | |
| Ucb, INC. | $1,967.59 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Biogen, INC. | $1,842.37 | 2019-2025 | Tysabri, Vumerity, Avonex |
| Pfizer INC. | $1,485.65 | 2021-2025 | |
| Acadia Pharmaceuticals INC | $1,394.83 | 2019-2025 | Nuplazid, Daybue |
| Eisai INC. | $1,346.09 | 2019-2025 | |
| Lundbeck LLC | $1,210.77 | 2019-2025 | Vyepti, Rexulti |
| Novartis Pharmaceuticals Corporation | $1,177.33 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $1,165.27 | 2019-2025 | Ingrezza, Ongentys |
| Lilly USA, LLC | $1,028.04 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Alexion Pharmaceuticals, INC. | $998.49 | 2019-2025 | Ultomiris, Soliris |
| Emd Serono, INC. | $987.70 | 2019-2023 | Mavenclad |
| Biohaven Pharmaceuticals, INC. | $910.84 | 2020-2021 | |
| Mdd US Operations, LLC | $894.08 | 2019-2025 | Gocovri, Qelbree, Gocovri |
| Amgen INC. | $869.13 | 2019-2025 | Uplizna |
Show all 86 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Futrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.